MedTrace Logo

Real-world Dosing Patterns of Rivaroxaban in the United States

NCT03242278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12507

Last updated 2023-06-28

No results posted yet for this study

Summary

The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban.

The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

As prescribed by treating physicians

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-12
Primary Completion
2016-03-01
Completion
2016-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03242278 on ClinicalTrials.gov